Since CDK4/6 inhibitors re-sensitize PDX tumors to HER2-targeted therapies and delay tumor recurrence in vivo, CDK4/6 inhibitors may also re-sensitize resistant HER2+ human BRCs to EGFR/HER2 inhibition [50]. The gene discussed is EGFR; the disease is neoplasm.